Genetic variation of human neutrophil Fcγ receptors and SIRPα in antibody-dependent cellular cytotoxicity towards cancer cells

European Journal of Immunology

Volumn 48, Issue 2, 2018, Pages 344-354

  Treffers, Louise W ^a   Zhao, Xi Wen ^a   van der Heijden, Joris ^a   Nagelkerke, Sietse Q ^a   van Rees, Dieke J ^a   Gonzalez, Patricia ^a   Geissler, Judy ^a   Verkuijlen, Paul ^a   van Houdt, Michel ^a   de Boer, Martin ^a   Kuijpers, Taco W ^a   van den Berg, Timo K ^a,b   Matlung, Hanke L ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cancer; CD47 SIRP interactions; Fc R; Neutrophils; Trastuzumab

Indexed keywords

CD47 ANTIGEN; FC RECEPTOR; REGULATOR PROTEIN; SIGNAL REGULATORY PROTEIN ALPHA; TRASTUZUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DIFFERENTIATION ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FC RECEPTOR IIA; IMMUNOGLOBULIN RECEPTOR; SIRPA PROTEIN, HUMAN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BREAST CANCER; CONTROLLED STUDY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC VARIATION; HUMAN; HUMAN CELL; LEUKOCYTE ACTIVATION; NEUTROPHIL; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SK-BR-3 CELL LINE; BREAST TUMOR; FEMALE; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; PHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME; TUMOR CELL LINE;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, DIFFERENTIATION; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CD47 ANTIGEN; CELL LINE, TUMOR; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; IMMUNOTHERAPY; LINKAGE DISEQUILIBRIUM; NEUTROPHILS; POLYMORPHISM, GENETIC; RECEPTOR, ERBB-2; RECEPTORS, IGG; RECEPTORS, IMMUNOLOGIC; TRASTUZUMAB; TREATMENT OUTCOME;

EID: 85041797726     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201747215     Document Type: Article

References (53)

1. Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P. and Watier, H., Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002. 99: 754–758.
2. van der Heijden, J., Breunis, W. B., Geissler, J., de Boer, M., van den Berg, T. K. and Kuijpers, T. W., Phenotypic variation in IgG receptors by nonclassical FCGR2C alleles. J. Immunol. 2012. 188: 1318–1324.
3. van der Heijden, J., Geissler, J., van Mirre, E., van Deuren, M., van der Meer, J. W., Salama, A., van den Berg, T. K. et al., A novel splice variant of FcgammaRIIa: a risk factor for anaphylaxis in patients with hypogammaglobulinemia. J. Allergy Clin. Immunol. 2013. 131: 1408–1416 e1405.
4. Breunis, W. B., van Mirre, E., Geissler, J., Laddach, N., Wolbink, G., van der Schoot, E., de Haas, M. et al., Copy number variation at the FCGR locus includes FCGR3A, FCGR2C and FCGR3B but not FCGR2A and FCGR2B. Hum. Mutat. 2009. 30: E640-E650.
5. Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D. et al., Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol. 2008. 26: 1789–1796.
6. Zhang, W., Gordon, M., Schultheis, A. M., Yang, D. Y., Nagashima, F., Azuma, M., Chang, H. M. et al., FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J. Clin. Oncol. 2007. 25: 3712–3718.
7. Stockmeyer, B., Beyer, T., Neuhuber, W., Repp, R., Kalden, J. R., Valerius, T. and Herrmann, M., Polymorphonuclear granulocytes induce antibody-dependent apoptosis in human breast cancer cells. J. Immunol. 2003. 171: 5124–5129.
8. Breunis, W. B., van Mirre, E., Bruin, M., Geissler, J., de Boer, M., Peters, M., Roos, D. et al., Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura. Blood 2008. 111: 1029–1038.
9. van der Heijden, J., Nagelkerke, S., Zhao, X., Geissler, J., Rispens, T., van den Berg, T. K. and Kuijpers, T. W., Haplotypes of FcgammaRIIa and FcgammaRIIIb polymorphic variants influence IgG-mediated responses in neutrophils. J. Immunol. 2014. 192: 2715–2721.
10. Nagelkerke, S. Q., Tacke, C. E., Breunis, W. B., Geissler, J., Sins, J. W., Appelhof, B., van den Berg, T. K. et al., Nonallelic homologous recombination of the FCGR2/3 locus results in copy number variation and novel chimeric FCGR2 genes with aberrant functional expression. Genes Immun. 2015. 16: 422–429.
11. Chao, M. P., Alizadeh, A. A., Tang, C., Myklebust, J. H., Varghese, B., Gill, S., Jan, M. et al., Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 2010. 142: 699–713.
12. Weiskopf, K., Ring, A. M., Ho, C. C., Volkmer, J. P., Levin, A. M., Volkmer, A. K., Ozkan, E. et al., Engineered SIRPalpha variants as immunotherapeutic adjuvants to anticancer antibodies. Science 2013. 341: 88–91.
13. Zhao, X. W., van Beek, E. M., Schornagel, K., Van der Maaden, H., Van Houdt, M., Otten, M. A., Finetti, P. et al., CD47-signal regulatory protein-alpha (SIRPalpha) interactions form a barrier for antibody-mediated tumor cell destruction. Proc. Natl. Acad. Sci. USA 2011. 108: 18342–18347.
14. Treffers, L. W., Hiemstra, I. H., Kuijpers, T. W., van den Berg, T. K. and Matlung, H. L., Neutrophils in cancer. Immunol. Rev. 2016. 273: 312–328.
15. van Rees, D. J., Szilagyi, K., Kuijpers, T. W., Matlung, H. L. and van den Berg, T. K., Immunoreceptors on neutrophils. Semin. Immunol. 2016. 28: 94–108.
16. Matlung, H. L., Szilagyi, K., Barclay, N. A. and van den Berg, T. K., The CD47-SIRPalpha signaling axis as an innate immune checkpoint in cancer. Immunol. Rev. 2017. 276: 145–164.
17. Takenaka, K., Prasolava, T. K., Wang, J. C., Mortin-Toth, S. M., Khalouei, S., Gan, O. I., Dick, J. E. et al., Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells. Nat. Immunol. 2007. 8: 1313–1323.
18. Rodriguez, P. L., Harada, T., Christian, D. A., Pantano, D. A., Tsai, R. K. and Discher, D. E., Minimal “Self” peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science 2013. 339: 971–975.
19. Hatherley, D., Graham, S. C., Turner, J., Harlos, K., Stuart, D. I. and Barclay, A. N., Paired receptor specificity explained by structures of signal regulatory proteins alone and complexed with CD47. Mol. Cell 2008. 31: 266–277.
20. Zhao, X. W., Matlung, H. L., Kuijpers, T. W. and van den Berg, T. K., On the mechanism of CD47 targeting in cancer. Proc. Natl. Acad. Sci. USA 2012. 109: E2843; author reply E2844-2845.
21. Zhao, X. W., Kuijpers, T. W. and van den Berg, T. K., Is targeting of CD47-SIRPalpha enough for treating hematopoietic malignancy? Blood 2012. 119: 4333–4334; author reply 4334–4335.
22. Nagelkerke, S. Q., Dekkers, G., Kustiawan, I., van de Bovenkamp, F. S., Geissler, J., Plomp, R., Wuhrer, M. et al., Inhibition of FcgammaR-mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and FcgammaRIIb in human macrophages. Blood 2014. 124: 3709–3718.
23. Ravetch, J. V. and Bolland, S., IgG Fc receptors. Annu. Rev. Immunol. 2001. 19: 275–290.
24. Golay, J., Da Roit, F., Bologna, L., Ferrara, C., Leusen, J. H., Rambaldi, A., Klein, C. et al., Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood 2013. 122: 3482–3491.
25. Vossebeld, P. J., Homburg, C. H., Roos, D. and Verhoeven, A. J., The anti-Fc gamma RIII mAb 3G8 induces neutrophil activation via a cooperative actin of Fc gamma RIIIb and Fc gamma RIIa. Int. J. Biochem. Cell Biol. 1997. 29: 465–473.
26. Kakinoki, Y., Kubota, H. and Yamamoto, Y., CD64 surface expression on neutrophils and monocytes is significantly up-regulated after stimulation with granulocyte colony-stimulating factor during CHOP chemotherapy for patients with non-Hodgkin's lymphoma. Int. J. Hematol. 2004. 79: 55–62.
27. Rodriguez, J., Zarate, R., Bandres, E., Boni, V., Hernandez, A., Sola, J. J., Honorato, B. et al., Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer. Eur. J. Cancer 2012. 48: 1774–1780.
28. Niederer, H. A., Willcocks, L. C., Rayner, T. F., Yang, W., Lau, Y. L., Williams, T. N., Scott, J. A. et al., Copy number, linkage disequilibrium and disease association in the FCGR locus. Hum. Mol. Genet. 2010. 19: 3282–3294.
29. Bux, J., Stein, E. L., Bierling, P., Fromont, P., Clay, M., Stroncek, D. and Santoso, S., Characterization of a new alloantigen (SH) on the human neutrophil Fc gamma receptor IIIb. Blood 1997. 89: 1027–1034.
30. Tsang, A. S. M. W., Nagelkerke, S. Q., Bultink, I. E., Geissler, J., Tanck, M. W., Tacke, C. E., Ellis, J. A. et al., Fc-gamma receptor polymorphisms differentially influence susceptibility to systemic lupus erythematosus and lupus nephritis. Rheumatology (Oxford) 2016. 55: 939–948.
31. Willcocks, L. C., Lyons, P. A., Clatworthy, M. R., Robinson, J. I., Yang, W., Newland, S. A., Plagnol, V. et al., Copy number of FCGR3B, which is associated with systemic lupus erythematosus, correlates with protein expression and immune complex uptake. J. Exp. Med. 2008. 205: 1573–1582.
32. Bredius, R. G., Fijen, C. A., De Haas, M., Kuijper, E. J., Weening, R. S., Van de Winkel, J. G. and Out, T. A., Role of neutrophil Fc gamma RIIa (CD32) and Fc gamma RIIIb (CD16) polymorphic forms in phagocytosis of human IgG1- and IgG3-opsonized bacteria and erythrocytes. Immunology 1994. 83: 624–630.
33. Salmon, J. E., Edberg, J. C., Brogle, N. L. and Kimberly, R. P., Allelic polymorphisms of human Fc gamma receptor IIA and Fc gamma receptor IIIB. Independent mechanisms for differences in human phagocyte function. J. Clin. Invest. 1992. 89: 1274–1281.
34. Bruhns, P., Iannascoli, B., England, P., Mancardi, D. A., Fernandez, N., Jorieux, S. and Daeron, M., Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009. 113: 3716–3725.
35. Schneider-Merck, T., Lammerts van Bueren, J. J., Berger, S., Rossen, K., van Berkel, P. H., Derer, S., Beyer, T. et al., Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J. Immunol. 2010. 184: 512–520.
36. Weng, W. K. and Levy, R., Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 2003. 21: 3940–3947.
37. Gavin, P. G., Song, N., Kim, S. R., Lipchik, C., Johnson, N. L., Bandos, H., Finnigan, M. et al., Association of polymorphisms in FCGR2A and FCGR3A with degree of trastuzumab benefit in the adjuvant treatment of ERBB2/HER2-positive breast cancer: analysis of the NSABP B-31 Trial. JAMA Oncol. 2017. 3: 335–341.
38. Norton, N., Olson, R. M., Pegram, M., Tenner, K., Ballman, K. V., Clynes, R., Knutson, K. L. et al., Association studies of Fcgamma receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831. Cancer Immunol. Res. 2014. 2: 962–969.
39. Hurvitz, S. A., Betting, D. J., Stern, H. M., Quinaux, E., Stinson, J., Seshagiri, S., Zhao, Y. et al., Analysis of Fcgamma receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin. Cancer Res. 2012. 18: 3478–3486.
40. Tate, B. J., Witort, E., McKenzie, I. F. and Hogarth, P. M., Expression of the high responder/non-responder human Fc gamma RII. Analysis by PCR and transfection into FcR-COS cells. Immunol. Cell Biol. 1992. 70(Pt 2): 79–87.
41. Cartron, G., Ohresser, M., Salles, G., Solal-Celigny, P., Colombat, P. and Watier, H., Neutrophil role in in vivo anti-lymphoma activity of rituximab: FCGR3B-NA1/NA2 polymorphism does not influence response and survival after rituximab treatment. Ann. Oncol. 2008. 19: 1485–1487.
42. Metelitsa, L. S., Gillies, S. D., Super, M., Shimada, H., Reynolds, C. P. and Seeger, R. C., Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis. Blood 2002. 99: 4166–4173.
43. Kushner, B. H. and Cheung, N. K., Absolute requirement of CD11/CD18 adhesion molecules, FcRII and the phosphatidylinositol-linked FcRIII for monoclonal antibody-mediated neutrophil antihuman tumor cytotoxicity. Blood 1992. 79: 1484–1490.
44. Ottonello, L., Epstein, A. L., Dapino, P., Barbera, P., Morone, P. and Dallegri, F., Monoclonal Lym-1 antibody-dependent cytolysis by neutrophils exposed to granulocyte-macrophage colony-stimulating factor: intervention of FcgammaRII (CD32), CD11b-CD18 integrins, and CD66b glycoproteins. Blood 1999. 93: 3505–3511.
45. Kurlander, R. J., Blockade of Fc receptor-mediated binding to U-937 cells by murine monoclonal antibodies directed against a variety of surface antigens. J. Immunol. 1983. 131: 140–147.
46. Mancardi, D. A., Albanesi, M., Jonsson, F., Iannascoli, B., Van Rooijen, N., Kang, X., England, P. et al., The high-affinity human IgG receptor FcgammaRI (CD64) promotes IgG-mediated inflammation, anaphylaxis, and antitumor immunotherapy. Blood 2013. 121: 1563–1573.
47. Bruhns, P., Properties of mouse and human IgG receptors and their contribution to disease models. Blood 2012. 119: 5640–5649.
48. Lewis, L. D., Cole, B. F., Wallace, P. K., Fisher, J. L., Waugh, M., Guyre, P. M., Fanger, M. W. et al., Pharmacokinetic-pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with interferon gamma: a multiple-dose phase-I study in patients with advanced cancer which overexpresses HER-2/neu. J. Immunol. Methods 2001. 248: 149–165.
49. Michon, J. M., Gey, A., Moutel, S., Tartour, E., Meresse, V., Fridman, W. and Teillaud, J. L., In vivo induction of functional Fc gammaRI (CD64) on neutrophils and modulation of blood cytokine mRNA levels in cancer patients treated with G-CSF (rMetHuG-CSF). Br. J. Haematol. 1998. 100: 550–556.
50. McCarthy, D. A., Macey, M. G., Streetly, M., Schey, S. A. and Brown, K. A., The neutropenia induced by the thalidomide analogue CC-4047 in patients with multiple myeloma is associated with an increased percentage of neutrophils bearing CD64. Int. Immunopharmacol. 2006. 6: 1194–1203.
51. Roos, D. and de Boer, M., Purification and cryopreservation of phagocytes from human blood. Methods Enzymol. 1986. 132: 225–243.
52. Schouten, J. P., McElgunn, C. J., Waaijer, R., Zwijnenburg, D., Diepvens, F. and Pals, G., Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002. 30: e57.
53. Flesch, B. K., Doose, S., Siebert, R., Ntambi, E. and Neppert, J., FCGR3 variants and expression of human neutrophil antigen-1a, -1b, and -1c in the populations of northern Germany and Uganda. Transfusion 2002. 42: 469–475.